A preclinical study evaluating INOLIFE’s needle-free injection system (INOJEX) with cannabidiol (CBD) for the treatment of neuropathic pain and associated anxiety-depressive symptoms in rats.

Chronic neuropathic pain affects millions of Canadians for which the government spends ~$6 billion a year on treatment. It is therefore imperative to find new therapies with few side effects and high therapeutic efficacy. This study will examine the therapeutic properties of cannabidiol (CBD), which is a non-intoxicating component of cannabis. Studies have shown that CBD has ant-inflammatory, anti-anxiety, and pain-relieving effects. Our main objective is to test the effects of CBD using Inolife’s needle-free injection system (Inojex) in an animal model of neuropathic pain and understand its mechanism of action. The Inojex system gives us an opportunity to deliver cannabis-based drugs to patients unable to consume cannabis through traditional oral routes. This system could revolutionize a safe and effective way of dosing and administrating cannabis for medical purposes in animals and eventually in patients.TO BE CONT''D

Intern: 
Antonio Farina
Faculty Supervisor: 
Gabriella Gobbi
Province: 
Quebec
University: 
Partner: 
Partner University: 
Discipline: 
Program: